DEPLOYDatabase

Robot model

Toumai

MicroPort MedBot developed the Toumai, a four-arm laparoscopic surgical robot that became the first Chinese-developed surgical robot to receive NMPA regulatory…

Track ToumaiGet notified of verified changes
Manufacturer
MicroPort MedBot
Form factor
surgical
Lifecycle
active

Verified profile

  • 2

    Sources on record

  • 0

    Tracked changes

  • Updated recently

    Last verified change

How we verify →

Overview

MicroPort MedBot developed the Toumai, a four-arm laparoscopic surgical robot that became the first Chinese-developed surgical robot to receive NMPA regulatory clearance, granted in January 2022. The system uses 3D HD vision and wristed surgical instruments for minimally invasive procedures across urology, gynecology, and general surgery. A single-port variant, the Toumai SP, received separate NMPA clearance in March 2025, and a tele-operative version received NMPA approval in May 2025 as the first tele-surgical robot authorized for commercial clinical use globally.

Verified vs. claimed

Verified deployments
None on file
Sources on file
2 sources, view all

Safety record

No incidents on record for Toumai.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (2)

  1. MicroPort Toumai Surgical Robot Receives NMPA Approval | MicroPort MedBot · https://www.medbotsurgical.com/en/news/53.html
  2. Toumai Laparoscopic Surgical Robot | MicroPort · https://microport.com/news/microport-toumai-surgical-robot-receives-nmpa-approval-becoming-the-first-commercialized-four-arm-laparoscopic-surgical-robot-developed-in-china

Common questions

What is Toumai?
MicroPort MedBot developed the Toumai, a four-arm laparoscopic surgical robot that became the first Chinese-developed surgical robot to receive NMPA regulatory clearance, granted in January 2022. The system uses 3D HD vision and wristed surgical instruments for minimally invasive procedures across urology, gynecology, and general surgery. A single-port variant, the Toumai SP, received separate NMPA clearance in March 2025, and a tele-operative version received NMPA approval in May 2025 as the first tele-surgical robot authorized for commercial clinical use globally.
Who makes Toumai?
Toumai is made by MicroPort MedBot, based in Shanghai, China.
Where is Toumai deployed?
No verified deployments of Toumai are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
Is Toumai safe?
Toumai has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 2 sources (no primary) · last reviewed 2026-06-28

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-06-28

Maturity + lifecycle

Lifecycle: active

Architectural position

Cohort: surgical

Sources by quality tier

2
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Toumai.